An FDA advisory panel recommended the approval of alirocumab and evolocumab last week, and the cardiovascular medications are expected to be approved this summer. However, the drugs may cost up to $10,000 per year and may be too expensive for some patients, USA Today reports.
Executive Editor
Tim Casey joined TriMed Media Group in 2015 as Executive Editor. For the previous four years, he worked as an editor and writer for HMP Communications, primarily focused on covering managed care issues and reporting from medical and health care conferences. He was also a staff reporter at the Sacramento Bee for more than four years covering professional, college and high school sports. He earned his undergraduate degree in psychology from the University of Notre Dame and his MBA degree from Georgetown University.